AddLife boosts UK medtech footprint with acquisition of BioSpectrum

AddLife AB ( ($SE:ALIF.B) ) has issued an update.

AddLife AB has expanded its Medtech business area by acquiring UK-based BioSpectrum Ltd, a fast-growing distributor of surgical solutions in urology, gynaecology and general surgery. BioSpectrum, headquartered in Newark, generates about GBP 6 million in annual revenue, employs 16 staff and supplies single-use endoscopes, consumables, surgical staplers and capital equipment to hospitals and clinics across the UK via NHS framework contracts.

The deal, effective 11 March 2026, strengthens AddLife’s pan-European footprint and its presence in advanced, niche surgical product segments with strong long-term growth potential. Management expects the transaction to have a marginally positive effect on earnings per share in 2026, while offering BioSpectrum enhanced resources, a broader European platform and a long-term growth path under the AddLife umbrella, benefiting employees, suppliers and customers.

The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK157.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.

More about AddLife AB

AddLife AB is a Stockholm-listed independent life science partner that supplies high-quality medical and laboratory products, services and advisory solutions to public and private healthcare providers across Europe. The group employs about 2,300 people in roughly 85 operating subsidiaries and generates annual net sales exceeding SEK 10 billion, positioning it as a significant consolidator in the European medtech and life science markets.

Average Trading Volume: 190,716

Technical Sentiment Signal: Sell

Current Market Cap: SEK17.37B

See more data about ALIF.B stock on TipRanks’ Stock Analysis page.